News

Four-year Follow-up Data on SPRINT® PNS for Low Back Pain Highlights Sustained Pain Relief Avoiding Costly and Invasive Treatments

CLEVELAND, April 29, 2025 (GLOBE NEWSWIRE) -- SPR announced the publication of long-term follow-up survey data from a prospective, multicenter…

8 months ago

Four-year Follow-up Data on SPRINT® PNS for Low Back Pain Highlights Sustained Pain Relief Avoiding Costly and Invasive Treatments

CLEVELAND, April 29, 2025 (GLOBE NEWSWIRE) -- SPR announced the publication of long-term follow-up survey data from a prospective, multicenter…

8 months ago

Myriad Genetics to Release First Quarter 2025 Financial Results on May 6, 2025

Management will participate in two upcoming investor healthcare conferencesSALT LAKE CITY, April 29, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc.…

8 months ago

Myriad Genetics to Release First Quarter 2025 Financial Results on May 6, 2025

Management will participate in two upcoming investor healthcare conferencesSALT LAKE CITY, April 29, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc.…

8 months ago

Orchestra BioMed Receives FDA Approval of IDE to Initiate U.S. Coronary Pivotal Trial Randomizing First-in-Class Sirolimus-AngioInfusion Balloon, Virtue SAB, Head-to-Head with Paclitaxel-Coated Balloon

Orchestra BioMed’s Virtue® Sirolimus AngioInfusion Balloon™ (“Virtue SAB”) is the only non-coated drug-eluting balloon system under clinical investigation worldwide and has…

8 months ago

Orchestra BioMed Receives FDA Approval of IDE to Initiate U.S. Coronary Pivotal Trial Randomizing First-in-Class Sirolimus-AngioInfusion Balloon, Virtue SAB, Head-to-Head with Paclitaxel-Coated Balloon

Orchestra BioMed’s Virtue® Sirolimus AngioInfusion Balloon™ (“Virtue SAB”) is the only non-coated drug-eluting balloon system under clinical investigation worldwide and has…

8 months ago

Four-year Follow-up Data on SPRINT® PNS for Low Back Pain Highlights Sustained Pain Relief Avoiding Costly and Invasive Treatments

Four-year Follow-up Data on SPRINT® PNS for Low Back Pain Highlights Sustained Pain Relief Avoiding Costly and Invasive Treatments

Myriad Genetics to Release First Quarter 2025 Financial Results on May 6, 2025

Myriad Genetics to Release First Quarter 2025 Financial Results on May 6, 2025

Orchestra BioMed Receives FDA Approval of IDE to Initiate U.S. Coronary Pivotal Trial Randomizing First-in-Class Sirolimus-AngioInfusion Balloon, Virtue SAB, Head-to-Head with Paclitaxel-Coated Balloon

Orchestra BioMed Receives FDA Approval of IDE to Initiate U.S. Coronary Pivotal Trial Randomizing First-in-Class Sirolimus-AngioInfusion Balloon, Virtue SAB, Head-to-Head with Paclitaxel-Coated Balloon

Zelluna ASA – Annual General Meeting held on April 29, 2025

Zelluna ASA – Annual General Meeting held on April 29, 2025

The International Myeloma Foundation Mourns the Loss of Board Member and Longtime Philanthropist John O’Dwyer

The International Myeloma Foundation Mourns the Loss of Board Member and Longtime Philanthropist John O’Dwyer